Jing Zhong

ORCID: 0000-0003-3090-787X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cardiovascular Effects of Exercise
  • Single-cell and spatial transcriptomics
  • Fibroblast Growth Factor Research
  • Thyroid Cancer Diagnosis and Treatment
  • Cardiac pacing and defibrillation studies
  • Acute Lymphoblastic Leukemia research
  • Acute Myeloid Leukemia Research
  • Neuroblastoma Research and Treatments
  • Cardiovascular Function and Risk Factors
  • Cardiomyopathy and Myosin Studies
  • Mitochondrial Function and Pathology
  • Heart Failure Treatment and Management
  • Viral Infections and Immunology Research
  • Congenital heart defects research
  • Wnt/β-catenin signaling in development and cancer
  • Angiogenesis and VEGF in Cancer
  • Chemotherapy-induced cardiotoxicity and mitigation

Guangzhou Institutes of Biomedicine and Health
2025

Guangzhou Medical University
2025

Chinese Academy of Sciences
2025

Army Medical University
2023

Xinqiao Hospital
2023

University of South China
2023

Qingdao University
2021

Fibroblast growth factor 1 (FGF1) is extensively amplified in many tumors and accelerates tumor invasion metastasis. However, the role precise molecular mechanism by which FGF1 participates thyroid cancer (TC) are still unclear.

10.1530/ec-23-0014 article EN cc-by-nc-nd Endocrine Connections 2023-03-23

Doxorubicin is a cornerstone chemotherapeutic drug widely used to treat various cancers; its dose-dependent cardiomyopathy, however, one of the leading causes treatment-associated mortality in cancer survivors. Patients’ threshold doses doxorubicin-induced cardiomyopathy (DIC) and heart failure are highly variable, mostly due genetic variations individuals’ genomes. However, susceptibility DIC remains largely unidentified. Here, we combined approach zebrafish (Danio rerio) animal model with...

10.1155/2021/8569921 article EN cc-by BioMed Research International 2021-07-15

Abstract Background The effects of novel-dose Sacubitril/Valsartan (S/V) in patients with heart failure (HF) the real world have not been adequately studied. We examined risk for all-cause re-admission HF taking S/V and possible mediator role left ventricular reverse remodeling (LVRR). Methods Results There were 464 recruited from December 2017 to September 2021 our hospital a median follow-up 660 days (range, 17-1494). Model 1 2 developed based on results univariable competing analysis,...

10.1101/2023.02.08.23285680 preprint EN medRxiv (Cold Spring Harbor Laboratory) 2023-02-10
Coming Soon ...